Detalhe da pesquisa
1.
Extracellular matrix remodeling proteins as biomarkers for clinical assessment and treatment outcomes in eosinophilic esophagitis.
BMC Gastroenterol
; 23(1): 357, 2023 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845632
2.
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Gastroenterology
; 159(5): 1672-1685.e5, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32721437
3.
Food-induced immediate response of the esophagus-A newly identified syndrome in patients with eosinophilic esophagitis.
Allergy
; 76(1): 339-347, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662110
4.
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Gastroenterology
; 157(1): 74-86.e15, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922997
5.
Correction: Extracellular matrix remodeling proteins as biomarkers for clinical assessment and treatment outcomes in eosinophilic esophagitis.
BMC Gastroenterol
; 23(1): 407, 2023 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993792
6.
Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
United European Gastroenterol J
; 10(3): 330-343, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35412032
7.
Acid perfusion test: a useful test for evaluating esophageal acid sensitivity?
Dig Dis Sci
; 51(5): 873, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16642424